Market Cap 5.85B
Revenue (ttm) 627.24M
Net Income (ttm) -177.03M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -28.22%
Debt to Equity Ratio 0.30
Volume 1,480,700
Avg Vol 1,234,196
Day's Range N/A - N/A
Shares Out 184.57M
Stochastic %K 13%
Beta 0.23
Analysts Strong Sell
Price Target $75.86

Company Profile

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candida...

Industry: Biotechnology
Sector: Healthcare
Phone: 737 317 5050
Address:
2101 Cottontail Lane, Somerset, United States
UknZ
UknZ Oct. 19 at 12:09 PM
$LEGN https://stocks.apple.com/A8_T3rXG_TNO3xUgMyg8x-A
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 10:44 AM
HC Wainwright & Co. has adjusted their stance on Legend Biotech ( $LEGN ), setting the rating to Buy with a target price of 75 → 60.
0 · Reply
DoctrBenway
DoctrBenway Oct. 16 at 2:29 PM
$LEGN Initiated medium position @ 33.5
0 · Reply
Quantumup
Quantumup Oct. 16 at 11:51 AM
Stifel resumed coverage of $ACLX at a Buy rating and a $129 PT $LEGN - $JNJ $GILD Stifel said in its note:
0 · Reply
ottobotto1
ottobotto1 Oct. 14 at 12:39 PM
$LEGN https://seekingalpha.com/news/4503869-legend-biotech-nets-524m-sales-carvykti-q3
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 14 at 8:10 AM
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print $JNJ $PTGX $LEGN https://stocktwits.com/news/equity/markets/johnson-and-johnson-stock-falls-premarket-investors-q3-print/ch6mSIXR3lw
0 · Reply
DiamondHandsBTW
DiamondHandsBTW Oct. 10 at 11:49 PM
$LEGN $JNJ Not good...https://www.reuters.com/legal/litigation/us-fda-adds-boxed-warning-jj-legend-biotechs-cancer-therapy-2025-10-10/
0 · Reply
UknZ
UknZ Oct. 10 at 1:50 PM
$LEGN anytime now …
0 · Reply
JarvisFlow
JarvisFlow Oct. 9 at 1:46 PM
JP Morgan has updated their rating for Legend Biotech ( $LEGN ) to Overweight with a price target of 76.
0 · Reply
UknZ
UknZ Oct. 8 at 3:35 PM
$LEGN https://stocks.apple.com/A6xXy9fcjRfeZ2H7tthJcHA
0 · Reply
Latest News on LEGN
Legend Biotech Appoints Carlos Santos as Chief Financial Officer

Aug 18, 2025, 8:00 AM EDT - 2 months ago

Legend Biotech Appoints Carlos Santos as Chief Financial Officer


Legend Biotech Corporation (LEGN) Q1 2025 Earnings Call Transcript

May 13, 2025, 11:15 AM EDT - 5 months ago

Legend Biotech Corporation (LEGN) Q1 2025 Earnings Call Transcript


Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 12:06 PM EDT - 8 months ago

Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call Transcript


Legend Biotech: The Story Brightens

Dec 5, 2024, 2:14 PM EST - 11 months ago

Legend Biotech: The Story Brightens


Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Nov 4, 2024, 7:30 AM EST - 1 year ago

Legend Biotech Appoints Alan Bash as President of CARVYKTI®


Legend Biotech to set up new R&D facility in Philadelphia

Oct 3, 2024, 7:41 AM EDT - 1 year ago

Legend Biotech to set up new R&D facility in Philadelphia


UknZ
UknZ Oct. 19 at 12:09 PM
$LEGN https://stocks.apple.com/A8_T3rXG_TNO3xUgMyg8x-A
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 10:44 AM
HC Wainwright & Co. has adjusted their stance on Legend Biotech ( $LEGN ), setting the rating to Buy with a target price of 75 → 60.
0 · Reply
DoctrBenway
DoctrBenway Oct. 16 at 2:29 PM
$LEGN Initiated medium position @ 33.5
0 · Reply
Quantumup
Quantumup Oct. 16 at 11:51 AM
Stifel resumed coverage of $ACLX at a Buy rating and a $129 PT $LEGN - $JNJ $GILD Stifel said in its note:
0 · Reply
ottobotto1
ottobotto1 Oct. 14 at 12:39 PM
$LEGN https://seekingalpha.com/news/4503869-legend-biotech-nets-524m-sales-carvykti-q3
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 14 at 8:10 AM
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print $JNJ $PTGX $LEGN https://stocktwits.com/news/equity/markets/johnson-and-johnson-stock-falls-premarket-investors-q3-print/ch6mSIXR3lw
0 · Reply
DiamondHandsBTW
DiamondHandsBTW Oct. 10 at 11:49 PM
$LEGN $JNJ Not good...https://www.reuters.com/legal/litigation/us-fda-adds-boxed-warning-jj-legend-biotechs-cancer-therapy-2025-10-10/
0 · Reply
UknZ
UknZ Oct. 10 at 1:50 PM
$LEGN anytime now …
0 · Reply
JarvisFlow
JarvisFlow Oct. 9 at 1:46 PM
JP Morgan has updated their rating for Legend Biotech ( $LEGN ) to Overweight with a price target of 76.
0 · Reply
UknZ
UknZ Oct. 8 at 3:35 PM
$LEGN https://stocks.apple.com/A6xXy9fcjRfeZ2H7tthJcHA
0 · Reply
DiamondHandsBTW
DiamondHandsBTW Oct. 7 at 3:05 PM
$LEGN word to management and genscript clearly what you have been doing is not working so change it
0 · Reply
FillScavenger
FillScavenger Oct. 5 at 9:55 AM
$LEGN Biotech with commercial launch. Volatility expected. High short interest. Potential squeeze setup.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Oct. 3 at 8:35 PM
The attachment shows the change in share price since 8/29/2025 for all 20 commercial-stage bios with market caps north of $275MM. The table also shows current FY2028 revenue multiples. Note a majority of bios with market caps north of $1B trade for less than 3.0X FY2028 analyst estimates where the average like bio in non-oncology trades for 3.1X FY2028 consensus. The XBI is up 15% since 8/29/2025, generally beating gains in all but 2 of the 20 in the group. $LEGN $NVCR & $SNDX trade at the lowest multiples of FY2028 revenues in the peer group with market caps north of $1B. NVCR is one of the 2 to beat the XBI since the end of August 2025. $FENC has been for sale for years & trades at the highest FY28 of the group with market caps less than $1B. Investors may recall $RIGL traded for over $40/share after a massive Q2 25 beat & raise. We're merely sharing an observation. This is not investment advice.
2 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 4:55 PM
$LEGN Really good write-up that perfectly summarizes LEGN's present situation. So if you want to bring your LEGN knowledge up to date or just discover LEGN, this is required reading. https://beyondspx.com/quote/LEGN/analysis/legend-biotech-carvykti-s-unmatched-efficacy-powers-profitability-and-next-gen-cell-therapy-leadership-legn
0 · Reply
DiamondHandsBTW
DiamondHandsBTW Oct. 3 at 2:04 PM
$LEGN sell the company morons
0 · Reply
UknZ
UknZ Oct. 3 at 1:49 PM
$LEGN going below 30?
0 · Reply
Bornjever
Bornjever Oct. 1 at 2:58 PM
$LEGN $MRUS $SNDX $URGN $ZYME yes LEGN is especially hot since going down nicely but do not forget ARQT as earn coming end of October.
1 · Reply
DiamondHandsBTW
DiamondHandsBTW Sep. 30 at 6:42 PM
$LEGN Management is killing shareholders XBI is up 10% YTD while this is flat.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Sep. 30 at 1:51 PM
The attachment compares $MRUS (post GMAB M&A) market cap as a multiple of cumulative 10-year analyst revenue estimates of 0.61X to 5 peer commercial-stage oncology focused bios. $LEGN is forecast to generate over $1B in FY2025 revenues & trades at roughly one-third MRUS' 10-year revenue multiple. Other notables include $SNDX & $URGN that trade at less than 0.20X 10-year revenue forecasts. Incidentally, the SNDX & URGN multiples exclude the highest analyst estimate post FY2030. One analyst forecasts SNDX to generate over $3B in annual sales by FY2034. Again this specific forecast is excluded from the SNDX multiple calculation (same with URGN). DAWN trades @ 0.12X 10-year forecasts but we suspect the DAWN forecast assumes Firefly is a success. It appears $ZYME trades at 0.50X 10-year analyst forecasts. We're genuinely curious if investors do not believe these are appropriate peers or comps (and why). This is otherwise not investment advice.
4 · Reply
SweepCastApp
SweepCastApp Sep. 29 at 11:19 AM
$LEGN: Unusual Options Activity Alerted CALL flow observed 105x contracts at Strike price of $35 Exp on 02/20/2026 with Premium of $37K and showing BEARISH Sentiment
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 26 at 12:34 PM
Enter: $LEGN OCT 17 2025 $35 CALLS Buy in Price: $0.75 - $2.25 Take Profit: $1.41 Stop Bleeding: $0.66 ROI Potential: 88% Exit Within: 252 Minutes https://moneygroup.us/alerts
0 · Reply
skinkman
skinkman Sep. 26 at 1:58 AM
$LEGN liquidity grab?
0 · Reply